Novartis | NVS - Current Assets


Novartis reported $26.61B in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
AbbVie USD 33.67B 140M Jun/2026
Amgen USD 34.96B 3.49B Jun/2026
AstraZeneca USD 27.97B 1.65B Jun/2026
Bausch Health Companies USD 6.52B 544M Jun/2026
Biogen USD 7.31B 1.88B Jun/2026
Bristol-Myers Squibb USD 28.58B 1.37B Jun/2026
Canopy Growth CAD 529.47M 4.8M Mar/2026
Corcept Therapeutics USD 439.68M 13.64M Jun/2026
Drreddys Laboratories INR 301.98B 298.66B Mar/2026
Eli Lilly USD 64.67B 9.84B Jun/2026
Gilead Sciences USD 12.53B 6.11B Jun/2026
GlaxoSmithKline GBP 17.56B 202M Jun/2026
Glaxosmithkline GBP 17.76B 5.83B Mar/2026
J&J USD 59.77B 601M Jun/2026
Merck USD 36.68B 1.66B Jun/2026
Novartis USD 27.35B 744M Jun/2026
Novartis USD 26.61B 3.85B Mar/2026
Pacira USD 615.21M 100.25M Jun/2026
Perrigo USD 2.45B 260.7M Jun/2026
Pfizer USD 41.36B 1.46B Jun/2026
Phibro Animal Health USD 935.51M 41.44M Jun/2026
Prestige Brands USD 496.81M 65.33M Jun/2026
Roche Holding CHF 35.44B 3.29B Jun/2026
Sanofi EUR 31.52B 1.36B Jun/2026
Sanofi EUR 30.16B 789M Mar/2026
Supernus Pharmaceuticals USD 723.5M 8.08M Jun/2026
Zoetis USD 6.36B 118M Jun/2026